Therefore, strategies that displace PLB from binding to SERCA2a, such as a newly identified DWORF peptide, hold promise in restoring SERCA2a function in cardiac disease (D. M. Anderson et al., 2015; Nelson et al., 2016). Here, PLN is linked to heart disorder.